KR20040096541A - 인자 Ｘａ 활성을 저해하는 화합물 - Google Patents
인자 Ｘａ 활성을 저해하는 화합물 Download PDFInfo
- Publication number
- KR20040096541A KR20040096541A KR10-2004-7011732A KR20047011732A KR20040096541A KR 20040096541 A KR20040096541 A KR 20040096541A KR 20047011732 A KR20047011732 A KR 20047011732A KR 20040096541 A KR20040096541 A KR 20040096541A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- phenyl
- phenylamino
- pyran
- yloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 78
- 108010074860 Factor Xa Proteins 0.000 title claims abstract description 13
- 230000000694 effects Effects 0.000 title claims description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 208000001435 Thromboembolism Diseases 0.000 claims abstract description 10
- 208000005189 Embolism Diseases 0.000 claims abstract description 9
- 238000009472 formulation Methods 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 6
- -1 C 1 -C 4 alkyloxy Chemical group 0.000 claims description 55
- 125000001072 heteroaryl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 25
- 229910052760 oxygen Inorganic materials 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 22
- 125000003342 alkenyl group Chemical group 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000000304 alkynyl group Chemical group 0.000 claims description 19
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 17
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 239000001301 oxygen Substances 0.000 claims description 14
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 150000003254 radicals Chemical class 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000006413 ring segment Chemical group 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 125000003147 glycosyl group Chemical group 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 206010051113 Arterial restenosis Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 229910052721 tungsten Inorganic materials 0.000 claims description 2
- 238000007631 vascular surgery Methods 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 229910052709 silver Inorganic materials 0.000 claims 1
- 239000004332 silver Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000002265 prevention Effects 0.000 abstract description 6
- 238000001425 electrospray ionisation time-of-flight mass spectrometry Methods 0.000 description 63
- 125000004432 carbon atom Chemical group C* 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 16
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 229940127219 anticoagulant drug Drugs 0.000 description 8
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 229910052794 bromium Inorganic materials 0.000 description 7
- 230000015271 coagulation Effects 0.000 description 7
- 238000005345 coagulation Methods 0.000 description 7
- 229920000669 heparin Polymers 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 206010047249 Venous thrombosis Diseases 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 150000002527 isonitriles Chemical class 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- FLCJAEREAWXGKS-UHFFFAOYSA-N 2-(5-carbamimidoyl-2-hydroxyanilino)-N-(4-morpholin-4-ylphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=C(O)C(NC(C(=O)NC=2C=CC(=CC=2)N2CCOCC2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 FLCJAEREAWXGKS-UHFFFAOYSA-N 0.000 description 3
- 102100023804 Coagulation factor VII Human genes 0.000 description 3
- 206010051055 Deep vein thrombosis Diseases 0.000 description 3
- 108010023321 Factor VII Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 108010049003 Fibrinogen Proteins 0.000 description 3
- 102000008946 Fibrinogen Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010022562 Intermittent claudication Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940012413 factor vii Drugs 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 229940012952 fibrinogen Drugs 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 229940019333 vitamin k antagonists Drugs 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010054265 Factor VIIa Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108060005989 Tryptase Proteins 0.000 description 2
- 102000001400 Tryptase Human genes 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BGOFCVIGEYGEOF-UJPOAAIJSA-N helicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UJPOAAIJSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- YFUGCZFMYAAIAQ-UHFFFAOYSA-N n-(4-benzoylphenyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=CC(=CC=2)C(=O)C=2C=CC=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 YFUGCZFMYAAIAQ-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- BGOFCVIGEYGEOF-UHFFFAOYSA-N salicylaldehyde beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- MMZYCBHLNZVROM-UHFFFAOYSA-N 1-fluoro-2-methylbenzene Chemical compound CC1=CC=CC=C1F MMZYCBHLNZVROM-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- DXWFIDDDMXERHV-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-2-[3-ethoxy-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-n-(4-morpholin-4-ylphenyl)acetamide Chemical compound O1C(CO)C(O)C(O)C(O)C1OC=1C(OCC)=CC=CC=1C(C(=O)NC=1C=CC(=CC=1)N1CCOCC1)NC1=CC=CC(C(N)=N)=C1 DXWFIDDDMXERHV-UHFFFAOYSA-N 0.000 description 1
- SNXSJUSCOVJKAJ-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-2-[3-ethoxy-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-n-[4-(morpholine-4-carbonyl)phenyl]acetamide Chemical compound O1C(CO)C(O)C(O)C(O)C1OC=1C(OCC)=CC=CC=1C(C(=O)NC=1C=CC(=CC=1)C(=O)N1CCOCC1)NC1=CC=CC(C(N)=N)=C1 SNXSJUSCOVJKAJ-UHFFFAOYSA-N 0.000 description 1
- PFLCIRBJJSSQSE-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=C3OCCOC3=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 PFLCIRBJJSSQSE-UHFFFAOYSA-N 0.000 description 1
- HSQSYDLILYILJG-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(2,6-dimethylphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 HSQSYDLILYILJG-UHFFFAOYSA-N 0.000 description 1
- QOJGJRLIMDOLGY-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(2-methoxy-5-phenylphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound COC1=CC=C(C=2C=CC=CC=2)C=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 QOJGJRLIMDOLGY-UHFFFAOYSA-N 0.000 description 1
- WZZUQFJIUKMERK-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3,3-dimethylbutan-2-yl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C=1C=CC=C(OC2C(C(O)C(O)C(CO)O2)O)C=1C(C(=O)NC(C)C(C)(C)C)NC1=CC=CC(C(N)=N)=C1 WZZUQFJIUKMERK-UHFFFAOYSA-N 0.000 description 1
- IPLAKMDSXLGQPF-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3,3-diphenylpropyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 IPLAKMDSXLGQPF-UHFFFAOYSA-N 0.000 description 1
- OMCURLATUXOEQJ-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3,4-difluorophenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=C(F)C(F)=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 OMCURLATUXOEQJ-UHFFFAOYSA-N 0.000 description 1
- VCZJKQHHYSIHFD-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3,4-dimethoxyphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 VCZJKQHHYSIHFD-UHFFFAOYSA-N 0.000 description 1
- LBPFMXCUHZFVJG-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3,7-dimethylocta-2,6-dienyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C=1C=CC=C(OC2C(C(O)C(O)C(CO)O2)O)C=1C(C(=O)NCC=C(C)CCC=C(C)C)NC1=CC=CC(C(N)=N)=C1 LBPFMXCUHZFVJG-UHFFFAOYSA-N 0.000 description 1
- IUMZAEKFFMZZCG-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3-cyanophenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=C(C=CC=2)C#N)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 IUMZAEKFFMZZCG-UHFFFAOYSA-N 0.000 description 1
- SBOVPRRUAWAMJH-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3-morpholin-4-ylpropyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCCCN2CCOCC2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 SBOVPRRUAWAMJH-UHFFFAOYSA-N 0.000 description 1
- JPYLZSLJKHNKHG-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3-phenoxyphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=C(OC=3C=CC=CC=3)C=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 JPYLZSLJKHNKHG-UHFFFAOYSA-N 0.000 description 1
- UKOFAFKYOKPNSK-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3-phenylpropyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCCCC=2C=CC=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 UKOFAFKYOKPNSK-UHFFFAOYSA-N 0.000 description 1
- QFRKRPNUEKMFPF-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(3-propan-2-yloxypropyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C=1C=CC=C(OC2C(C(O)C(O)C(CO)O2)O)C=1C(C(=O)NCCCOC(C)C)NC1=CC=CC(C(N)=N)=C1 QFRKRPNUEKMFPF-UHFFFAOYSA-N 0.000 description 1
- MVXXYFJCPTYWOV-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(4-methoxyphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 MVXXYFJCPTYWOV-UHFFFAOYSA-N 0.000 description 1
- KLSKSRQQBOIPDV-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(4-methylpentan-2-yl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C=1C=CC=C(OC2C(C(O)C(O)C(CO)O2)O)C=1C(C(=O)NC(C)CC(C)C)NC1=CC=CC(C(N)=N)=C1 KLSKSRQQBOIPDV-UHFFFAOYSA-N 0.000 description 1
- BAIXKZHVFFRKDM-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(4-morpholin-4-ylphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=CC(=CC=2)N2CCOCC2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 BAIXKZHVFFRKDM-UHFFFAOYSA-N 0.000 description 1
- UCGJWEAYEAPZDF-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(4-nitrophenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 UCGJWEAYEAPZDF-UHFFFAOYSA-N 0.000 description 1
- QTJISFSGUZBCJK-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(4-phenoxyphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=CC(OC=3C=CC=CC=3)=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 QTJISFSGUZBCJK-UHFFFAOYSA-N 0.000 description 1
- DKTJWNFQNCUXEV-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(furan-2-ylmethyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCC=2OC=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 DKTJWNFQNCUXEV-UHFFFAOYSA-N 0.000 description 1
- GOSOEYSABIPDJV-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-(pyridin-4-ylmethyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCC=2C=CN=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 GOSOEYSABIPDJV-UHFFFAOYSA-N 0.000 description 1
- UWELARFBJGXMBS-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[(3,4-dichlorophenyl)methyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCC=2C=C(Cl)C(Cl)=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 UWELARFBJGXMBS-UHFFFAOYSA-N 0.000 description 1
- MSGZJAMBQFYQFM-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[(3,5-dimethylphenyl)methyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound CC1=CC(C)=CC(CNC(=O)C(NC=2C=C(C=CC=2)C(N)=N)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 MSGZJAMBQFYQFM-UHFFFAOYSA-N 0.000 description 1
- SEKYMHSAACIPRM-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[(3-methoxyphenyl)methyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound COC1=CC=CC(CNC(=O)C(NC=2C=C(C=CC=2)C(N)=N)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 SEKYMHSAACIPRM-UHFFFAOYSA-N 0.000 description 1
- JLPZSZBUOXXUHC-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[2-(3,4-dimethoxyphenyl)ethyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C1=C(OC)C(OC)=CC=C1CCNC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 JLPZSZBUOXXUHC-UHFFFAOYSA-N 0.000 description 1
- KOSCVIUFNLZITQ-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[2-(cyclohexen-1-yl)ethyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCCC=2CCCCC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 KOSCVIUFNLZITQ-UHFFFAOYSA-N 0.000 description 1
- QBKWMIQBKZNRSF-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[2-methyl-4-(morpholine-4-carbonyl)phenyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound CC1=CC(C(=O)N2CCOCC2)=CC=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 QBKWMIQBKZNRSF-UHFFFAOYSA-N 0.000 description 1
- KAGDISMIFRULKJ-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[3-(2-oxopyrrolidin-1-yl)propyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCCCN2C(CCC2)=O)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 KAGDISMIFRULKJ-UHFFFAOYSA-N 0.000 description 1
- UUUABDJMXJQSFY-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[3-chloro-4-(morpholine-4-carbonyl)phenyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=C(Cl)C(C(=O)N3CCOCC3)=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 UUUABDJMXJQSFY-UHFFFAOYSA-N 0.000 description 1
- HWZCNHYSRKFWKM-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[4-(morpholine-4-carbonyl)phenyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=CC(=CC=2)C(=O)N2CCOCC2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 HWZCNHYSRKFWKM-UHFFFAOYSA-N 0.000 description 1
- MJUSUSXLZSJXPQ-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[[2-(trifluoromethyl)phenyl]methyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCC=2C(=CC=CC=2)C(F)(F)F)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 MJUSUSXLZSJXPQ-UHFFFAOYSA-N 0.000 description 1
- NYMRSWOKNMASAR-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[[3-(trifluoromethyl)phenyl]methyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCC=2C=C(C=CC=2)C(F)(F)F)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 NYMRSWOKNMASAR-UHFFFAOYSA-N 0.000 description 1
- VCBDPXHYKBPZGF-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-[[4-(trifluoromethyl)phenyl]methyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 VCBDPXHYKBPZGF-UHFFFAOYSA-N 0.000 description 1
- XYVFXQUBPIUPCG-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-methyl-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C=1C=CC=C(OC2C(C(O)C(O)C(CO)O2)O)C=1C(C(=O)NC)NC1=CC=CC(C(N)=N)=C1 XYVFXQUBPIUPCG-UHFFFAOYSA-N 0.000 description 1
- DEEGWOHUYMKELA-UHFFFAOYSA-N 2-(3-carbamimidoylanilino)-n-quinolin-6-yl-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=C3C=CC=NC3=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 DEEGWOHUYMKELA-UHFFFAOYSA-N 0.000 description 1
- KSCKGLMJUPGGLE-UHFFFAOYSA-N 2-(5-carbamimidoyl-2-hydroxyanilino)-N-[4-(morpholine-4-carbonyl)phenyl]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=C(O)C(NC(C(=O)NC=2C=CC(=CC=2)C(=O)N2CCOCC2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 KSCKGLMJUPGGLE-UHFFFAOYSA-N 0.000 description 1
- REBWSFKBXIVNRQ-UHFFFAOYSA-N 2-(furan-3-yl)furan Chemical group C1=COC(C2=COC=C2)=C1 REBWSFKBXIVNRQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- SDKXIIHKAGFARP-UHFFFAOYSA-N 2-[5-carbamimidoyl-2-(methylamino)anilino]-n-(4-morpholin-4-ylphenyl)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound CNC1=CC=C(C(N)=N)C=C1NC(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)C(=O)NC1=CC=C(N2CCOCC2)C=C1 SDKXIIHKAGFARP-UHFFFAOYSA-N 0.000 description 1
- OTBDRIJEXMUOGU-UHFFFAOYSA-N 2-[[2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetyl]amino]benzoic acid Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C(=CC=CC=2)C(O)=O)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 OTBDRIJEXMUOGU-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- COJLEDKJRFSDTQ-UHFFFAOYSA-N 3-amino-4-chlorobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(Cl)C(N)=C1 COJLEDKJRFSDTQ-UHFFFAOYSA-N 0.000 description 1
- IPMPVLAASRKHRW-UHFFFAOYSA-N 3-amino-4-hydroxybenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(O)C(N)=C1 IPMPVLAASRKHRW-UHFFFAOYSA-N 0.000 description 1
- VWDSNVUXQDDXBN-UHFFFAOYSA-N 3-aminobenzenecarboximidamide Chemical compound NC(=N)C1=CC=CC(N)=C1 VWDSNVUXQDDXBN-UHFFFAOYSA-N 0.000 description 1
- 125000006284 3-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(F)=C1[H])C([H])([H])* 0.000 description 1
- 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
- BNDMHAXTNRDKHP-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(O)C([N+]([O-])=O)=C1 BNDMHAXTNRDKHP-UHFFFAOYSA-N 0.000 description 1
- INBLGVOPOSGVTA-UHFFFAOYSA-N 4-hydroxy-3-nitrobenzonitrile Chemical compound OC1=CC=C(C#N)C=C1[N+]([O-])=O INBLGVOPOSGVTA-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010001779 Ancrod Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- KSRBEVHQUNSSDA-UHFFFAOYSA-N C=1C=CC=C(C(NC=2C=C(C=CC=2)C(N)=N)C(=O)NC=2C=CC(=CC=2)N2CCOCC2)C=1OC1(C)OC(O)C(O)C(O)C1O Chemical compound C=1C=CC=C(C(NC=2C=C(C=CC=2)C(N)=N)C(=O)NC=2C=CC(=CC=2)N2CCOCC2)C=1OC1(C)OC(O)C(O)C(O)C1O KSRBEVHQUNSSDA-UHFFFAOYSA-N 0.000 description 1
- 102100029117 Coagulation factor X Human genes 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108010014172 Factor V Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- LNMJMCLTSMQTAL-UHFFFAOYSA-N NC(=N)C1=CC=C(Cl)C(NC(C(=O)NC=2C=CC(=CC=2)N2CCOCC2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 Chemical compound NC(=N)C1=CC=C(Cl)C(NC(C(=O)NC=2C=CC(=CC=2)N2CCOCC2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 LNMJMCLTSMQTAL-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 238000003482 Pinner synthesis reaction Methods 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JHTASDGAIUBRCS-UHFFFAOYSA-N [3,4,5-triacetyloxy-6-[2-[1-(5-carbamimidoyl-2-hydroxyanilino)-2-(4-morpholin-4-ylanilino)-2-oxoethyl]phenoxy]oxan-2-yl]methyl acetate Chemical compound CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(COC(=O)C)OC1OC1=CC=CC=C1C(C(=O)NC=1C=CC(=CC=1)N1CCOCC1)NC1=CC(C(N)=N)=CC=C1O JHTASDGAIUBRCS-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005354 acylalkyl group Chemical group 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004948 alkyl aryl alkyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- HSMPSHPWCOOUJH-UHFFFAOYSA-N anilinyl Chemical group [NH]C1=CC=CC=C1 HSMPSHPWCOOUJH-UHFFFAOYSA-N 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005018 aryl alkenyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229940105756 coagulation factor x Drugs 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 150000003997 cyclic ketones Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- FWFSEYBSWVRWGL-UHFFFAOYSA-N cyclohex-2-enone Chemical compound O=C1CCCC=C1 FWFSEYBSWVRWGL-UHFFFAOYSA-N 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000006202 diisopropylaminoethyl group Chemical group [H]C([H])([H])C([H])(N(C([H])([H])C([H])([H])*)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- YJSZPCWDRACASD-UHFFFAOYSA-N ethyl 3-[[2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetyl]amino]propanoate Chemical compound C=1C=CC=C(OC2C(C(O)C(O)C(CO)O2)O)C=1C(C(=O)NCCC(=O)OCC)NC1=CC=CC(C(N)=N)=C1 YJSZPCWDRACASD-UHFFFAOYSA-N 0.000 description 1
- 125000006534 ethyl amino methyl group Chemical group [H]N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940068628 helicin Drugs 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- BZQRBEVTLZHKEA-UHFFFAOYSA-L magnesium;trifluoromethanesulfonate Chemical compound [Mg+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F BZQRBEVTLZHKEA-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- JIQNWFBLYKVZFY-UHFFFAOYSA-N methoxycyclohexatriene Chemical compound COC1=C[C]=CC=C1 JIQNWFBLYKVZFY-UHFFFAOYSA-N 0.000 description 1
- DXOOTVRHSOXLSK-UHFFFAOYSA-N methyl 2-[[2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetyl]amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 DXOOTVRHSOXLSK-UHFFFAOYSA-N 0.000 description 1
- CBHSVMKEAZZRJS-UHFFFAOYSA-N methyl 2-[[2-[3-[n'-[(3-fluorophenyl)methyl]carbamimidoyl]anilino]-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetyl]amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(=N)NCC=2C=C(F)C=CC=2)=C1 CBHSVMKEAZZRJS-UHFFFAOYSA-N 0.000 description 1
- VZTSWMAPKVYAAZ-UHFFFAOYSA-N methyl 4-[[2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetyl]amino]benzoate Chemical compound C1=CC(C(=O)OC)=CC=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 VZTSWMAPKVYAAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000006452 multicomponent reaction Methods 0.000 description 1
- YZOPFKOLVKSNQE-UHFFFAOYSA-N n-(1,3-benzodioxol-5-ylmethyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NCC=2C=C3OCOC3=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 YZOPFKOLVKSNQE-UHFFFAOYSA-N 0.000 description 1
- RFDKQXUIAHOOTI-UHFFFAOYSA-N n-(2-benzoyl-4-chlorophenyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C(=CC(Cl)=CC=2)C(=O)C=2C=CC=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 RFDKQXUIAHOOTI-UHFFFAOYSA-N 0.000 description 1
- WZDFDVMPGRLSFH-UHFFFAOYSA-N n-(2-bromophenyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C(=CC=CC=2)Br)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 WZDFDVMPGRLSFH-UHFFFAOYSA-N 0.000 description 1
- JTIMLHMXUMBVAW-UHFFFAOYSA-N n-(3-acetylphenyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound CC(=O)C1=CC=CC(NC(=O)C(NC=2C=C(C=CC=2)C(N)=N)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 JTIMLHMXUMBVAW-UHFFFAOYSA-N 0.000 description 1
- FDSVVOPASGXHHC-UHFFFAOYSA-N n-(3-benzoylphenyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=C(C=CC=2)C(=O)C=2C=CC=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 FDSVVOPASGXHHC-UHFFFAOYSA-N 0.000 description 1
- OHVQJSTYFGWZDN-UHFFFAOYSA-N n-(3-butoxypropyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C=1C=CC=C(OC2C(C(O)C(O)C(CO)O2)O)C=1C(C(=O)NCCCOCCCC)NC1=CC=CC(C(N)=N)=C1 OHVQJSTYFGWZDN-UHFFFAOYSA-N 0.000 description 1
- GJHWAIQZSYWKGS-UHFFFAOYSA-N n-(4-acetylphenyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C1=CC(C(=O)C)=CC=C1NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 GJHWAIQZSYWKGS-UHFFFAOYSA-N 0.000 description 1
- JFBNJMBACDXTOG-UHFFFAOYSA-N n-(4-aminophenyl)-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound NC(=N)C1=CC=CC(NC(C(=O)NC=2C=CC(N)=CC=2)C=2C(=CC=CC=2)OC2C(C(O)C(O)C(CO)O2)O)=C1 JFBNJMBACDXTOG-UHFFFAOYSA-N 0.000 description 1
- CAPXXNAUCFNJCY-UHFFFAOYSA-N n-[(4-tert-butylphenyl)methyl]-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C1=CC(C(C)(C)C)=CC=C1CNC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 CAPXXNAUCFNJCY-UHFFFAOYSA-N 0.000 description 1
- RXPGDTADEPBKAN-UHFFFAOYSA-N n-[1-(4-bromophenyl)ethyl]-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C=1C=C(Br)C=CC=1C(C)NC(=O)C(C=1C(=CC=CC=1)OC1C(C(O)C(O)C(CO)O1)O)NC1=CC=CC(C(N)=N)=C1 RXPGDTADEPBKAN-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- AHKMAQGYDUWXRO-UHFFFAOYSA-N n-tert-butyl-2-(3-carbamimidoylanilino)-2-[2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]acetamide Chemical compound C=1C=CC=C(OC2C(C(O)C(O)C(CO)O2)O)C=1C(C(=O)NC(C)(C)C)NC1=CC=CC(C(N)=N)=C1 AHKMAQGYDUWXRO-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 108010014806 prothrombinase complex Proteins 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HZXJVDYQRYYYOR-UHFFFAOYSA-K scandium(iii) trifluoromethanesulfonate Chemical compound [Sc+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F HZXJVDYQRYYYOR-UHFFFAOYSA-K 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000005649 substituted arylene group Chemical group 0.000 description 1
- 125000005650 substituted phenylene group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical compound [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10204072.9 | 2002-01-31 | ||
| DE10204072A DE10204072A1 (de) | 2002-01-31 | 2002-01-31 | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
| DE10300049.6 | 2003-01-03 | ||
| DE10300049A DE10300049A1 (de) | 2003-01-03 | 2003-01-03 | Neue Verbindungen, die Faktor VIIa inhibieren |
| PCT/EP2003/001011 WO2003064440A1 (de) | 2002-01-31 | 2003-01-31 | Verbindungen, die faktor xa-aktivät inhibieren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040096541A true KR20040096541A (ko) | 2004-11-16 |
Family
ID=27664555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-7011732A Withdrawn KR20040096541A (ko) | 2002-01-31 | 2003-01-31 | 인자 Ｘａ 활성을 저해하는 화합물 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050049283A1 (https=) |
| EP (1) | EP1470143B1 (https=) |
| JP (1) | JP2005525325A (https=) |
| KR (1) | KR20040096541A (https=) |
| CN (1) | CN1322001C (https=) |
| AT (1) | ATE377017T1 (https=) |
| BR (1) | BR0307266A (https=) |
| CA (1) | CA2473169A1 (https=) |
| DE (1) | DE50308492D1 (https=) |
| MX (1) | MXPA04007461A (https=) |
| NZ (1) | NZ534238A (https=) |
| PL (1) | PL369772A1 (https=) |
| WO (1) | WO2003064440A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060135781A (ko) * | 2004-02-25 | 2006-12-29 | 라 졸라 파마슈티칼 컴파니 | 질병의 치료를 위한 아민 및 아미드 |
| ES2365815T3 (es) * | 2005-12-14 | 2011-10-11 | Bristol-Myers Squibb Company | Análogos de arilpropionamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor xia. |
| EP1981854B1 (en) | 2005-12-14 | 2011-06-01 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
| WO2017156071A1 (en) | 2016-03-09 | 2017-09-14 | Blade Therapeutics, Inc. | Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof |
| EP3481835A4 (en) | 2016-07-05 | 2020-02-26 | Blade Therapeutics, Inc. | CALPAIN MODULATORS AND THERAPEUTIC USE THEREOF |
| BR112019006110A2 (pt) | 2016-09-28 | 2019-09-10 | Blade Therapeutics Inc | moduladores de calpaína e usos terapêuticos dos mesmos |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2614893B1 (fr) * | 1987-05-04 | 1989-12-22 | Fournier Innovation Synergie | Nouveaux b-d-phenyl-thioxylosides, leur procede de preparation et leur application en therapeutique |
| EP0560568A3 (en) * | 1992-03-13 | 1994-06-29 | Takeda Chemical Industries Ltd | Hydroquinone derivatives and intermediates for production thereof |
| EP0921116B1 (de) * | 1997-12-04 | 2003-06-18 | F. Hoffmann-La Roche Ag | N-(4-carbamimido-phenyl)-glycinamidderivate |
| US6358960B1 (en) * | 1998-02-17 | 2002-03-19 | Ono Pharmaceutical Co., Ltd. | Amidino derivatives and drugs containing the same as the active ingredient |
| US6486129B1 (en) * | 1998-06-17 | 2002-11-26 | Akzo Nobel N.V. | Antithrombotic compounds |
| DE10041402A1 (de) * | 2000-08-23 | 2002-03-14 | Morphochem Ag | Neue Verbindungen, die Faktor Xa-Aktivität inhibieren |
| PT1336605E (pt) * | 2000-11-22 | 2006-06-30 | Astellas Pharma Inc | Derivados de fenol substituidos ou seus sais como inibidores do factor x de coagulacao |
-
2003
- 2003-01-31 BR BR0307266-5A patent/BR0307266A/pt not_active IP Right Cessation
- 2003-01-31 NZ NZ534238A patent/NZ534238A/en unknown
- 2003-01-31 AT AT03734605T patent/ATE377017T1/de not_active IP Right Cessation
- 2003-01-31 US US10/501,932 patent/US20050049283A1/en not_active Abandoned
- 2003-01-31 JP JP2003564060A patent/JP2005525325A/ja active Pending
- 2003-01-31 DE DE50308492T patent/DE50308492D1/de not_active Expired - Fee Related
- 2003-01-31 KR KR10-2004-7011732A patent/KR20040096541A/ko not_active Withdrawn
- 2003-01-31 CN CNB038031558A patent/CN1322001C/zh not_active Expired - Fee Related
- 2003-01-31 EP EP03734605A patent/EP1470143B1/de not_active Expired - Lifetime
- 2003-01-31 WO PCT/EP2003/001011 patent/WO2003064440A1/de not_active Ceased
- 2003-01-31 CA CA002473169A patent/CA2473169A1/en not_active Abandoned
- 2003-01-31 PL PL03369772A patent/PL369772A1/xx not_active Application Discontinuation
- 2003-01-31 MX MXPA04007461A patent/MXPA04007461A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005525325A (ja) | 2005-08-25 |
| DE50308492D1 (de) | 2007-12-13 |
| NZ534238A (en) | 2006-09-29 |
| CN1322001C (zh) | 2007-06-20 |
| EP1470143B1 (de) | 2007-10-31 |
| US20050049283A1 (en) | 2005-03-03 |
| MXPA04007461A (es) | 2005-07-13 |
| ATE377017T1 (de) | 2007-11-15 |
| WO2003064440A1 (de) | 2003-08-07 |
| CA2473169A1 (en) | 2003-08-07 |
| CN1625559A (zh) | 2005-06-08 |
| BR0307266A (pt) | 2004-12-07 |
| PL369772A1 (en) | 2005-05-02 |
| EP1470143A1 (de) | 2004-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001295507B2 (en) | Novel compounds inhibiting factor Xa activity | |
| JP4809570B2 (ja) | 第ＶＩＩａ因子阻害剤である（チオ）尿素誘導体、その製造方法およびその使用 | |
| KR100587434B1 (ko) | 신규 화합물 | |
| JP4274522B2 (ja) | Ｘａ因子阻害剤としてのグアニジンおよびアミジン誘導体 | |
| JP4658430B2 (ja) | Ｎ−グアニジノアルキルアミド、その製造、その使用およびそれを含む医薬調製物 | |
| KR20040096541A (ko) | 인자 Ｘａ 활성을 저해하는 화합물 | |
| JP5016178B2 (ja) | 抗血栓活性を有するマロンアミドおよびマロンアミド酸エステル誘導体、それらの製造および使用 | |
| AU2001293824A1 (en) | Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation and their use | |
| AU2005263600A1 (en) | Novel compounds that inhibit factor Xa activity | |
| US20060058389A1 (en) | Novel compounds that inhibit factor xa activity | |
| JP2002526531A (ja) | トロンビン阻害剤としてのベンズアミド誘導体 | |
| ZA200300258B (en) | New amidino derivatives and their use as thrombin inhibitors. | |
| CA2470811A1 (en) | Protease inhibitors of the coagulation cascade isolated from dysidea sponges | |
| CZ2003452A3 (en) | Data processing system, with an Internet connection facility has a structured program loaded in memory for use in assigning predetermined data from a multiplicity of data to hierarchical memory addresses | |
| MXPA00005483A (en) | New compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20040729 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |